Biotechnology Examples in 2026: 7 Cases Beyond Insulin
Introduction
Search for “biotechnology examples” and the same short list appears again and again: insulin made by bacteria, yogurt and cheese fermentation, pest-resistant crops. These examples are accurate, but they are also decades old. For students who need concrete examples and for readers who want to understand modern medicine, the textbook list no longer reflects what biotechnology actually does in 2026.
A more useful way to understand biotechnology today is through regenerative medicine. Its recent clinical results are well documented, and many of them are already reaching patients. This article covers seven cases:
- CRISPR-edited, immune-evasive insulin-producing cells
- A gene-edited treatment for sickle cell disease (Casgevy)
- CAR-T cell therapy and its remission data
- In-situ 3D-bioprinted skin
- Platelet-rich plasma (PRP) in everyday orthopedic care
- The growing number of FDA-approved cell and gene therapies
- Therapies derived from pluripotent stem cells
The article is written for two groups. The first is students and curious learners who want specific, citable examples. The second is patient-curious readers who want to know what these treatments look like in practice. The central argument is that regenerative medicine is no longer a minor chapter in the biotechnology story. In 2025 and 2026, it has become the field’s most visible proof point in real-world medicine.
Beyond Insulin: What Counts as Biotechnology in 2026
Regenerative medicine is a branch of translational research in tissue engineering and molecular biology. It works to replace, engineer, or regenerate human cells, tissues, or organs so they can function normally again. Researchers describe its aim as generating living, functional tissue capable of repairing or replacing tissues or organs that have lost function because of age, disease, damage, or congenital defects. One of the field’s ultimate goals is to produce patient-specific organs from pluripotent stem cells (PSCs).
Regulators treat this area as its own category. The U.S. Food and Drug Administration defines cellular therapy products as including cellular immunotherapies, cancer vaccines, and other autologous (patient-derived) and allogeneic (donor-derived) cells used for certain therapeutic indications. That definition covers hematopoietic stem cells as well as adult and embryonic stem cells. The World Health Organization uses a broader list that includes hematopoietic stem cells, skin grafts, expanded autologous cells, recombinant oncolytic viruses, novel gene editing technologies, and engineered tissues.
These definitions show how much the field has changed. Producing insulin with bacteria was a major achievement of the 1980s. Current work goes much further: scientists now edit, engineer, and even print living human cells directly. None of the examples below is speculative. Each one appears in clinical trial results, FDA approval records, or market data from 2025 and 2026.
1. CRISPR-Edited, Immune-Evasive Insulin-Producing Cells
This case follows directly from the textbook insulin example. In the older model, bacteria in a fermentation tank produce insulin, and patients inject it. In the new approach, living human cells produce insulin inside the patient’s own body.
In December 2024, a 42-year-old man in Sweden with type 1 diabetes received 17 injections of genetically altered pancreatic cells into his left arm. It was the first human test of this treatment.
How It Works: Hypoimmune Cell Engineering
The researchers used CRISPR gene editing to remove specific surface proteins from donated beta cells. These are the proteins that normally trigger immune rejection. Once they were removed, the cells were far less likely to be detected and attacked by the recipient’s immune system.
The purpose was to deliver insulin-producing cells that the immune system effectively cannot see. If the approach succeeds at scale, it could remove one of the largest obstacles in cell transplantation: the need for lifelong immunosuppressive drugs, which carry significant risks of their own.
The Clinical Evidence: A Landmark Human Case
The first published results were encouraging. The injected cells:
- Stayed alive for at least three months
- Began releasing insulin
- Avoided destruction by the patient’s immune system
Both Nature and Science covered the case as a first-in-human milestone, which places it among the most closely followed diabetes research results of recent years.
Why This Matters More Than Textbook Insulin
Textbook insulin production is a way to manufacture a drug. This case is about restoring a bodily function using engineered living cells. A patient on conventional insulin therapy must manage the disease every day. A patient whose own body contains working, immune-evasive beta cells could, in principle, make insulin naturally again.
The idea also reaches beyond diabetes. Hypoimmune cell engineering could eventually apply to other autoimmune and metabolic conditions in which transplanted cells now require heavy immune suppression.
2. Gene-Edited Cure for Sickle Cell Disease: Casgevy
The insulin model depends on daily management. Casgevy represents a different model: a potential one-time treatment that addresses the genetic cause of the disease.
The Science Behind Exa-Cel
The therapy edits a specific gene in the patient’s blood stem cells. The edit increases production of fetal hemoglobin, a form of the oxygen-carrying protein that people normally make before birth.
In sickle cell disease, faulty hemoglobin causes red blood cells to take on a rigid, crescent shape. These sickled cells can block blood vessels and cause the painful episodes known as vaso-occlusive crises. Higher levels of fetal hemoglobin help red blood cells keep their normal shape, which can prevent these crises from happening.
Clinical Impact and Regulatory Milestone
Casgevy is one of the first CRISPR-based gene editing therapies approved for clinical use in a genetic blood disorder. It demonstrated that gene editing can move from a research tool to a regulated treatment. It is also part of the broader trend of faster regulatory clearance discussed in Case 6.
3. CAR-T Cell Therapy: Engineering Immune Cells to Fight Cancer
CAR-T cell therapy is a leading example of engineered cell-based cancer treatment. In this approach, a patient’s own immune cells are reprogrammed to find and attack cancer cells. It also shows that cellular biotechnology has moved from experimental treatment to standard care for certain blood cancers.
How CAR-T Reprograms the Immune System
The process has three main steps:
- Collection: T-cells, a type of white blood cell, are extracted from the patient’s blood.
- Engineering: In a laboratory, the T-cells are genetically modified to express chimeric antigen receptors (CARs). These engineered receptors recognize specific markers on cancer cells.
- Reinfusion: The modified cells are infused back into the patient, where they multiply and target the cancer.
Seven CAR-T therapies are now FDA-approved: Abecma, Aucatzyl, Breyanzi, Carvykti, Kymriah, Tecartus, and Yescarta.
Remission Data From the ELIANA Trial and Beyond
The results in this area are substantial. The pivotal phase 2 ELIANA trial reported:
- An 81% overall remission rate
- An 80% six-month relapse-free survival rate among patients who responded
These results came from a heavily pretreated population, meaning patients whose cancer had not responded to other therapies.
Longer-term data are also strong. In diffuse large B-cell lymphoma, CAR-T therapy has raised five-year overall survival above 50%, compared with about 15% with salvage chemotherapy.
These outcomes help explain why oncology is the largest application segment in the regenerative medicine market, with roughly 32% share in 2024.
4. In-Situ 3D-Bioprinted Skin
3D bioprinting is one of the most visually striking examples of biotechnology moving from the laboratory to the operating room. It combines biotechnology with robotics and materials science, not only molecular biology.
Robotic Bioprinting Technology Explained
Researchers have developed a surgical robot that can 3D bioprint directly into a wound. The robot deposits a cell-based construct that rebuilds skin across all layers.
The key advance is printing in situ, meaning directly on the patient. Earlier methods printed tissue separately and then grafted it onto the wound. That approach requires handling fragile tissue and fitting it to a wound’s irregular shape. Printing directly into the wound allows the construct to match the wound’s exact contours.
From Porcine Model to First-in-Human Trial
The system followed a standard validation path. Researchers first tested it in a porcine (pig) model, which is widely used because pig skin closely resembles human skin. The system then advanced to a first-in-human trial.
As the technology matures, it could benefit several groups:
- Burn patients, who need large areas of skin rebuilt quickly
- Chronic wound patients, such as people with diabetic ulcers that do not heal well
- Reconstructive surgery patients, who need precise, layered tissue restoration
5. Platelet-Rich Plasma (PRP): Biotechnology Already in Everyday Use
Many readers may not realize that platelet-rich plasma counts as biotechnology. PRP is already widely available and used in many clinics. It connects the advanced examples above, such as CRISPR and CAR-T, with routine clinical practice.
The Science of Autologous Blood-Based Healing
PRP starts with a small sample of the patient’s blood. The sample is processed to concentrate platelets and the growth factors they carry, and the concentrate is then applied to injured or degenerating tissue to support repair.
PRP does not involve gene editing or donor cells. It relies only on the patient’s own biological material, which makes it a low-barrier entry point to regenerative medicine.
Everyday Orthopedic Applications
PRP is well established in orthopedic and sports medicine. Clinicians use it to:
- Augment surgical repair of tendons, including the rotator cuff, Achilles, and hip gluteal tendons
- Treat chronic conditions such as tennis elbow and rotator cuff tendonitis
- Help manage knee osteoarthritis symptoms, with studies indicating that PRP can regulate inflammatory pathways
Of all the examples in this article, PRP is the one readers are most likely to have heard about from a physician, surgeon, or physical therapist.
6. The Expanding Landscape of FDA-Approved Cell and Gene Therapies
The individual cases above are part of a much larger pattern. As of late 2025, 46 cell and gene therapies had been approved in the United States, a number explored in more detail in this cell therapy review. That number reflects a mature, regulated field, not a handful of experimental treatments.
Umbilical Cord Blood Derivatives and Market Segmentation
The approvals fall into several categories:
| Category | Approvals | Share |
|---|---|---|
| Umbilical cord blood derivatives | 9 of 46 | 19.6% |
| CAR-T cell therapies | 7 of 46 | 15.2% |
| Exosome therapies | 0 of 46 | 0% |
Umbilical cord blood derivatives form the largest group. CAR-T therapies are also a major category, which reflects their clinical importance. No exosome therapies have received FDA approval yet, despite a promising clinical trial pipeline. This gap shows where the field is still developing.
What 46 Approvals Signal About the Pace of Innovation
The pace of approvals is increasing. Eight cell and gene therapy approvals occurred in 2024 alone. Regulators in the United States, Europe, and China now clear late-stage candidates within 12 to 18 months. Only five years ago, decade-long timelines were typical.
This change suggests that regenerative medicine has moved from rare breakthrough to routine regulatory category, with established review pathways and a steady flow of approved products.
7. Pluripotent Stem Cell-Derived Therapies: The Next Frontier
Products derived from human pluripotent stem cells (hPSCs) are the emerging edge of regenerative biotechnology. They build on the earlier examples in this article. The CRISPR-edited beta cell case focused on replacing a single cell type. hPSC-based work aims at more complex tissue and organ regeneration.
Engineering Patient-Specific Tissues and Organs
Pluripotent stem cells can, in principle, develop into almost any cell type in the body. That ability supports one of regenerative medicine’s long-term goals: generating patient-specific organs.
Most current cell therapies replace or reprogram one type of cell, such as T-cells in CAR-T or blood stem cells in Casgevy. hPSC research aims to regenerate whole tissues or organs. A patient-specific organ grown from the patient’s own cells could, in theory, reduce both donor shortages and the risk of rejection.
Where the Research Pipeline Is Headed
Researchers have documented continued growth in hPSC-derived products entering interventional clinical trials. Beyond diabetes and blood disorders, possible applications include:
- Neurological conditions, such as Parkinson’s disease, where specific neurons are lost
- Organ-level regeneration, which would repair or replace damaged organs rather than individual cell populations
Expectations should remain realistic. hPSC-derived therapies are still an active research area and are not widely available treatments. This sets them apart from more established examples such as CAR-T, Casgevy, and PRP.
Why Regenerative Medicine Is Biotechnology’s Most Visible Proof Point
Market data support the argument that regenerative medicine is central to modern biotechnology:
- The global regenerative medicine market was valued at USD 35.5 billion in 2024.
- It is estimated at USD 48.3 billion for 2026.
- It is projected to reach USD 90.0 billion by 2030, a compound annual growth rate of 16.8%.
Cell therapies are the main driver of this growth. They were projected to hold 49.7% of the market in 2025, supported by their use in tissue repair, organ regeneration, and personalized medicine. Oncology remains the largest therapeutic category by market share, which is consistent with CAR-T’s clinical results.
These figures connect back to the seven examples. Engineered beta cells, gene-edited stem cells, reprogrammed immune cells, bioprinted skin, and PRP injections are part of a fast-growing, heavily funded segment of medicine. In 2026, regenerative medicine deserves to be the lead example of biotechnology, not a footnote after insulin and yogurt.
Conclusion
The seven examples form a continuum:
- Cellular-level editing: CRISPR-edited beta cells and Casgevy
- Engineered immune therapies: CAR-T
- Tissue-level innovation: in-situ bioprinted skin
- Everyday clinical practice: PRP
- System-level scale: 46 FDA-approved cell and gene therapies
- Research frontier: pluripotent stem cell-derived therapies
Each example is supported by clinical trial results, regulatory records, or market data. Together, they show the direction biotechnology has taken, with fewer laboratory proofs of concept and more living, working treatments reaching patients. For anyone asking “what are examples of biotechnology,” these cases offer a current, evidence-based answer that goes well beyond the textbook list.
Explore Regenerative Medicine Options
Readers who are considering regenerative treatments may want to learn more about options that are available today, such as PRP and stem cell-based therapies. Adia Med offers regenerative medicine services. Readers interested in specific treatment options should contact Adia Med directly to learn what is currently available.
Not every regenerative approach suits every condition, and outcomes vary from person to person. The best next step is to consult a qualified provider, who can review an individual’s medical history, discuss the current evidence, and explain which approaches, if any, may be appropriate.
